Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes

Marimar Hernandez-Perez, Gaurav Chopra, Jonathan Fine, Abass M. Conteh, Ryan M. Anderson, Amelia Linnemann, Chanelle Benjamin, Jennifer B. Nelson, Kara S. Benninger, Jerry L. Nadler, David J. Maloney, Sarah A. Tersey, Raghu Mirmira

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Islet β-cell dysfunction and aggressive macrophage activity are early features in the pathogenesis of type 1 diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is induced in β-cells and macrophages during T1D and produces proinflammatory lipids and lipid peroxides that exacerbate β-cell dysfunction and macrophage activity. Inhibition of 12/15-LOX provides a potential therapeutic approach to prevent glycemic deterioration in T1D. Two inhibitors recently identified by our groups through screening efforts, ML127 and ML351, have been shown to selectively target 12/15-LOX with high potency. Only ML351 exhibited no apparent toxicity across a range of concentrations in mouse islets, and molecular modeling has suggested reduced promiscuity of ML351 compared with ML127. In mouse islets, incubation with ML351 improved glucose-stimulated insulin secretion in the presence of proinflammatory cytokines and triggered gene expression pathways responsive to oxidative stress and cell death. Consistent with a role for 12/15-LOX in promoting oxidative stress, its chemical inhibition reduced production of reactive oxygen species in both mouse and human islets in vitro. In a streptozotocin-induced model of T1D in mice, ML351 prevented the development of diabetes, with coincident enhancement of nuclear Nrf2 in islet cells, reduced β-cell oxidative stress, and preservation of β-cell mass. In the nonobese diabetic mouse model of T1D, administration of ML351 during the prediabetic phase prevented dysglycemia, reduced β-cell oxidative stress, and increased the proportion of anti-inflammatory macrophages in insulitis. The data provide the first evidence to date that small molecules that target 12/15-LOX can prevent progression of β-cell dysfunction and glycemic deterioration in models of T1D.

Original languageEnglish (US)
Pages (from-to)2875-2887
Number of pages13
JournalDiabetes
Volume66
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Type 1 Diabetes Mellitus
Oxidative Stress
Macrophages
Islets of Langerhans
Inbred NOD Mouse
Lipid Peroxides
Streptozocin
12-15-lipoxygenase
Reactive Oxygen Species
Cell Death
Anti-Inflammatory Agents
Insulin
Cytokines
Lipids
Gene Expression
Glucose

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. / Hernandez-Perez, Marimar; Chopra, Gaurav; Fine, Jonathan; Conteh, Abass M.; Anderson, Ryan M.; Linnemann, Amelia; Benjamin, Chanelle; Nelson, Jennifer B.; Benninger, Kara S.; Nadler, Jerry L.; Maloney, David J.; Tersey, Sarah A.; Mirmira, Raghu.

In: Diabetes, Vol. 66, No. 11, 01.11.2017, p. 2875-2887.

Research output: Contribution to journalArticle

Hernandez-Perez, M, Chopra, G, Fine, J, Conteh, AM, Anderson, RM, Linnemann, A, Benjamin, C, Nelson, JB, Benninger, KS, Nadler, JL, Maloney, DJ, Tersey, SA & Mirmira, R 2017, 'Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes', Diabetes, vol. 66, no. 11, pp. 2875-2887. https://doi.org/10.2337/db17-0215
Hernandez-Perez, Marimar ; Chopra, Gaurav ; Fine, Jonathan ; Conteh, Abass M. ; Anderson, Ryan M. ; Linnemann, Amelia ; Benjamin, Chanelle ; Nelson, Jennifer B. ; Benninger, Kara S. ; Nadler, Jerry L. ; Maloney, David J. ; Tersey, Sarah A. ; Mirmira, Raghu. / Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. In: Diabetes. 2017 ; Vol. 66, No. 11. pp. 2875-2887.
@article{be600050eb4e4c45aa56b501007ed638,
title = "Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes",
abstract = "Islet β-cell dysfunction and aggressive macrophage activity are early features in the pathogenesis of type 1 diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is induced in β-cells and macrophages during T1D and produces proinflammatory lipids and lipid peroxides that exacerbate β-cell dysfunction and macrophage activity. Inhibition of 12/15-LOX provides a potential therapeutic approach to prevent glycemic deterioration in T1D. Two inhibitors recently identified by our groups through screening efforts, ML127 and ML351, have been shown to selectively target 12/15-LOX with high potency. Only ML351 exhibited no apparent toxicity across a range of concentrations in mouse islets, and molecular modeling has suggested reduced promiscuity of ML351 compared with ML127. In mouse islets, incubation with ML351 improved glucose-stimulated insulin secretion in the presence of proinflammatory cytokines and triggered gene expression pathways responsive to oxidative stress and cell death. Consistent with a role for 12/15-LOX in promoting oxidative stress, its chemical inhibition reduced production of reactive oxygen species in both mouse and human islets in vitro. In a streptozotocin-induced model of T1D in mice, ML351 prevented the development of diabetes, with coincident enhancement of nuclear Nrf2 in islet cells, reduced β-cell oxidative stress, and preservation of β-cell mass. In the nonobese diabetic mouse model of T1D, administration of ML351 during the prediabetic phase prevented dysglycemia, reduced β-cell oxidative stress, and increased the proportion of anti-inflammatory macrophages in insulitis. The data provide the first evidence to date that small molecules that target 12/15-LOX can prevent progression of β-cell dysfunction and glycemic deterioration in models of T1D.",
author = "Marimar Hernandez-Perez and Gaurav Chopra and Jonathan Fine and Conteh, {Abass M.} and Anderson, {Ryan M.} and Amelia Linnemann and Chanelle Benjamin and Nelson, {Jennifer B.} and Benninger, {Kara S.} and Nadler, {Jerry L.} and Maloney, {David J.} and Tersey, {Sarah A.} and Raghu Mirmira",
year = "2017",
month = "11",
day = "1",
doi = "10.2337/db17-0215",
language = "English (US)",
volume = "66",
pages = "2875--2887",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes

AU - Hernandez-Perez, Marimar

AU - Chopra, Gaurav

AU - Fine, Jonathan

AU - Conteh, Abass M.

AU - Anderson, Ryan M.

AU - Linnemann, Amelia

AU - Benjamin, Chanelle

AU - Nelson, Jennifer B.

AU - Benninger, Kara S.

AU - Nadler, Jerry L.

AU - Maloney, David J.

AU - Tersey, Sarah A.

AU - Mirmira, Raghu

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Islet β-cell dysfunction and aggressive macrophage activity are early features in the pathogenesis of type 1 diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is induced in β-cells and macrophages during T1D and produces proinflammatory lipids and lipid peroxides that exacerbate β-cell dysfunction and macrophage activity. Inhibition of 12/15-LOX provides a potential therapeutic approach to prevent glycemic deterioration in T1D. Two inhibitors recently identified by our groups through screening efforts, ML127 and ML351, have been shown to selectively target 12/15-LOX with high potency. Only ML351 exhibited no apparent toxicity across a range of concentrations in mouse islets, and molecular modeling has suggested reduced promiscuity of ML351 compared with ML127. In mouse islets, incubation with ML351 improved glucose-stimulated insulin secretion in the presence of proinflammatory cytokines and triggered gene expression pathways responsive to oxidative stress and cell death. Consistent with a role for 12/15-LOX in promoting oxidative stress, its chemical inhibition reduced production of reactive oxygen species in both mouse and human islets in vitro. In a streptozotocin-induced model of T1D in mice, ML351 prevented the development of diabetes, with coincident enhancement of nuclear Nrf2 in islet cells, reduced β-cell oxidative stress, and preservation of β-cell mass. In the nonobese diabetic mouse model of T1D, administration of ML351 during the prediabetic phase prevented dysglycemia, reduced β-cell oxidative stress, and increased the proportion of anti-inflammatory macrophages in insulitis. The data provide the first evidence to date that small molecules that target 12/15-LOX can prevent progression of β-cell dysfunction and glycemic deterioration in models of T1D.

AB - Islet β-cell dysfunction and aggressive macrophage activity are early features in the pathogenesis of type 1 diabetes (T1D). 12/15-Lipoxygenase (12/15-LOX) is induced in β-cells and macrophages during T1D and produces proinflammatory lipids and lipid peroxides that exacerbate β-cell dysfunction and macrophage activity. Inhibition of 12/15-LOX provides a potential therapeutic approach to prevent glycemic deterioration in T1D. Two inhibitors recently identified by our groups through screening efforts, ML127 and ML351, have been shown to selectively target 12/15-LOX with high potency. Only ML351 exhibited no apparent toxicity across a range of concentrations in mouse islets, and molecular modeling has suggested reduced promiscuity of ML351 compared with ML127. In mouse islets, incubation with ML351 improved glucose-stimulated insulin secretion in the presence of proinflammatory cytokines and triggered gene expression pathways responsive to oxidative stress and cell death. Consistent with a role for 12/15-LOX in promoting oxidative stress, its chemical inhibition reduced production of reactive oxygen species in both mouse and human islets in vitro. In a streptozotocin-induced model of T1D in mice, ML351 prevented the development of diabetes, with coincident enhancement of nuclear Nrf2 in islet cells, reduced β-cell oxidative stress, and preservation of β-cell mass. In the nonobese diabetic mouse model of T1D, administration of ML351 during the prediabetic phase prevented dysglycemia, reduced β-cell oxidative stress, and increased the proportion of anti-inflammatory macrophages in insulitis. The data provide the first evidence to date that small molecules that target 12/15-LOX can prevent progression of β-cell dysfunction and glycemic deterioration in models of T1D.

UR - http://www.scopus.com/inward/record.url?scp=85037572648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037572648&partnerID=8YFLogxK

U2 - 10.2337/db17-0215

DO - 10.2337/db17-0215

M3 - Article

VL - 66

SP - 2875

EP - 2887

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -